Olanzapine pamoate

双羟萘酸奥氮平

Report date: 2024/08/12 20:00:30

Base Information

Drug NameOlanzapine pamoate
Drug Alias Name奥氮平双羟萘酸盐长效注射剂Zyprexa Relprevv
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2 (5-HT2) receptor antagonists
TargetsSerotonin 2 (5-HT2) receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2008/11/19
Country/TerritoryCanadaUnited StatesSlovakia +[14
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A